Advertisement
First agent in a new class of noncytotoxic cancer drugs
Understanding resistance in PARP inhibitor therapy
More time on drug may be needed
Data may lead to better treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Doctors need soft skills, too
Know Your Tumor initiative matches treatments with patients
Establishing best practices for seamless trial design
Understanding the role of patient sex may lead to personalized therapies
An international consensus statement on a subtype of a rare disease
How to care for patients with this rare, complex disease
Advertisement
Advertisement